Text size :

Da Silva (Gilead): “Over 18 million invested in 15 years to bring innovation in health”

ADNKRONOS

November 4, 2026

Rome, 4 Nov. (Adnkronos Health) – ‘The Gilead Calls represent a virtuous example of public-private collaboration, fundamental in our country to advance innovation in health. We have created a hub to support projects by researchers, patient associations, clinicians, and Third Sector entities. In 15 years, we have supported approximately 800 projects, with investments exceeding 18 million euros, involving over 5,000 patients and caregivers. But the most important result is the concrete impact on people’s lives.” This was stated by Frederico da Silva, vice president & general manager of Gilead Sciences Italy, at the event for the presentation and awarding of the winners of the 15th edition of the Gilead Calls, in Rome.

“Our commitment is to continue on this path and to keep investing in collaboration with all healthcare system stakeholders. To generate innovation and transform it into concrete benefits for patients, an ecosystem capable of fostering research and accompanying new solutions until they become accessible is needed. In Italy, we have carried out over 200 clinical studies in recent years, involving more than 150 centers of excellence and over 90,000 patients,” he added. Da Silva also recalled the “need for a system capable of attracting and valuing innovation,” transforming it into investments for the country’s health and growth. “Positive signals have come from the Ministry of Health, with measures such as early access to medicines and the possibility of keeping innovative medicines in the relevant fund for longer – he emphasized – Now it is important that the Budget Law makes available the necessary resources to translate these indications into concrete interventions, also to contain the payback, which has now exceeded 3 billion euros and weighs on companies that invest in research and innovation.”

Looking at Gilead’s evolution, da Silva recalled the results achieved in virology, particularly in the treatment of hepatitis and HIV, emphasizing that research continues to address unmet medical needs: “We are trying to bring to Italy an injectable drug to be administered twice a year, which prevents HIV infection almost 100% and can represent an important opportunity, especially for the most vulnerable populations.” The company has also expanded its research scope, which today includes solid oncology, hemato-oncology, with Car-T therapies, and inflammatory diseases. Among the areas of commitment, da Silva cited triple-negative metastatic breast cancer: “We have launched a drug that has transformed second-line treatment. It is now under evaluation by Aifa for first-line treatment, with the possibility of offering new opportunities to women affected by this form of disease.” “Gilead has been present in Italy for 26 years and has been promoting these calls for 15 years. The company has grown and diversified its activities, but our commitment to bringing innovation to people living with complex diseases and a strong need for new answers has not changed,” he concluded.

Jiji Press

Related

Page TOP